Aspirin response variability assessed with the PFA-100 device

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 968-969

  Reny, Jean Luc ^a,b   Quéré, Isabelle ^b   De Moerloose, Philippe ^c   Fontana, Pierre ^c,d  

^a Centre Hospitalier Beziers   (France)

^b University of Montpellier 1   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DEVICE; HUMAN; LETTER; PREVALENCE; PRIORITY JOURNAL; THROMBOCYTE; TREATMENT RESPONSE;

ASPIRIN; BLOOD PLATELETS; DRUG RESISTANCE; EQUIPMENT DESIGN; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TERMINOLOGY AS TOPIC;

EID: 43949135798     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-02-0123     Document Type: Letter

References (5)

1. Crescente M, Di Castelnuovo A, Iacoviello L, et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
2. Hovens MM, Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-181.
3. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 26; 336: 195-198.
4. Fontana P, Reny JL. Laboratory-defined aspirin resistance and recurrent cardiovascular events. Arch Intern Med 2008; 168: 549-550.
5. Reny JL, De Moerloose P, Dauzat M, et al. Use of the PFA-100™ closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.